On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia ...

July 2, 2012 — The outlook has never been better for patients with chronic myeloid leukemia (CML). Clinicians have an increasingly wide choice of drugs, between imatinib (Gleevec), dasatinib (Sprycel) ...

Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP). This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This ...

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy One hundred sixteen patients in durable CGCR, and ...

A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by asking five crucial questions to their oncologist. These queries cover ...

Life-long therapy with tyrosine kinase inhibitors (TKIs) is still the consensus treatment for patients with chronic myeloid leukemia (CML), but researchers are examining the feasibility of ...

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved ...

To our knowledge, up to now there is no evidence as to how mRNA gene expression of MDR1 before the onset of nilotinib can be used to determine treatment success under nilotinib second-line therapy.

Patients who achieved a major molecular response (MMR; BCR-ABL1 ≤0.1%) within 3 months had a 4-year progression-free survival (PFS) rate of about 80%, whereas those who did not meet that landmark ...

Novartis announced positive results from the primary analysis of ASC4FIRST, a pivotal phase III trial comparing Scemblix (asciminib) with investigators’ choice of tyrosine kinase inhibitor (TKI) ...

In patients with chronic myeloid leukemia (CML), disease in the initial chronic phase (CP) and subsequent progression are driven by the oncogenic activity of the BCR–ABL fusion kinase. Imatinib, a ...

"While MMR is the efficacy endpoint in CML, safety and tolerability are equally critical given the chronic nature of the disease. ELVN-001 was reported to be well tolerated across all evaluated doses ...